02 May 2016
EMA/251809/2016
Human Medicines Evaluation Division

# Targeted consultation on the guideline for development of new medicinal products for the treatment of rheumatoid arthritis (RA)

Invitation for expressions of interest

The European Medicines Agency (EMA) announces a one-day meeting to consult with stakeholders on the development of medicinal products for the treatment of rheumatoid arthritis. The workshop will be held at the EMA, in London, UK on 07 June 2016.

## Objectives of the planned meeting

- To provide interested stakeholders the opportunity to discuss the most up-to-date scientific views relevant to the development of medicinal products in RA with leading experts in this area
- To provide a forum of discussion on suitable study designs and possible label for new substances

## Main topics

1. Defining and selecting populations to be studied in RA
2. Extrapolation of clinical benefit between different populations in RA
3. Clinical trial designs
4. Endpoints in clinical trials

### Expressions of interest

We invite interested experts and stakeholders to send an expression of interest to attend this workshop by 20 May 2016 to RIWPsecretariat@ema.europa.eu, bearing in mind that the capacity will be limited.

Please note that registration will be restricted to a maximum of 2 participants per company.

A confirmation of registration will be sent by 25 May 2016.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
**Telephone** +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
**Send a question via our website** www.ema.europa.eu/contact